Abstract
The elimination of the cardioselective beta-adrenoceptor antagonist atenolol has been studied in 35 neonates by measuring drug concentration in cord blood and in blood obtained at 24 h by heel stab. Elimination rate was assessed by calculating the slopes of lines joining these two concentration points. The slopes had a mean of 0.043 h-1 (equivalent to a half-life of 16 h) and were normally distributed with 95% of values being in the range 0.02-0.066. There was no relationship between slope and neonatal weight or skinfold thickness, but most babies were at term and the range of these indices was narrow. Babies who developed a bradycardia had cord atenolol concentrations and slopes which did not differ significantly from those in babies without bradycardia. We conclude that atenolol elimination in the neonate is reduced when compared to adults. This prolonged elimination is consistent with the physiological characteristics of this age group and with previous observations on drugs eliminated by renal excretion.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aperia A., Broberger O., Elinder G., Herin P., Zetterström R. Postnatal development of renal function in pre-term and full-term infants. Acta Paediatr Scand. 1981 Mar;70(2):183–187. doi: 10.1111/j.1651-2227.1981.tb05539.x. [DOI] [PubMed] [Google Scholar]
- Assael B. M. Pharmacokinetics and drug distribution during postnatal development. Pharmacol Ther. 1982;18(2):159–197. doi: 10.1016/0163-7258(82)90066-3. [DOI] [PubMed] [Google Scholar]
- Cottrill C. M., McAllister R. G., Jr, Gettes L., Noonan J. A. Propranolol therapy during pregnancy, labor, and delivery: evidence for transplacental drug transfer and impaired neonatal drug disposition. J Pediatr. 1977 Nov;91(5):812–814. doi: 10.1016/s0022-3476(77)81049-4. [DOI] [PubMed] [Google Scholar]
- FRIIS-HANSEN B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics. 1961 Aug;28:169–181. [PubMed] [Google Scholar]
- Lundborg P., Agren G., Ervik M., Lindeberg S., Sandstrom B. Disposition of metoprolol in the newborn. Br J Clin Pharmacol. 1981 Oct;12(4):598–600. doi: 10.1111/j.1365-2125.1981.tb01276.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maclaurin J. C. Changes in body water distribution during the first two weeks of life. Arch Dis Child. 1966 Jun;41(217):286–291. doi: 10.1136/adc.41.217.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mason W. D., Winer N., Kochak G., Cohen I., Bell R. Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther. 1979 Apr;25(4):408–415. doi: 10.1002/cpt1979254408. [DOI] [PubMed] [Google Scholar]
- Rubin P. C., Butters L., Clark D. M., Reynolds B., Sumner D. J., Steedman D., Low R. A., Reid J. L. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet. 1983 Feb 26;1(8322):431–434. [PubMed] [Google Scholar]
- Rubin P. C., Scott P. J., McLean K., Pearson A., Ross D., Reid J. L. Atenolol disposition in young and elderly subjects. Br J Clin Pharmacol. 1982 Feb;13(2):235–237. doi: 10.1111/j.1365-2125.1982.tb01364.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Short C. R., Kinden D. A., Stith R. Fetal and neonatal development of the microsomal monooxygenase system. Drug Metab Rev. 1976;5(1):1–42. doi: 10.3109/03602537608995838. [DOI] [PubMed] [Google Scholar]
- Wallace S. Altered plasma albumin in the newborn infant. Br J Clin Pharmacol. 1977 Feb;4(1):82–85. doi: 10.1111/j.1365-2125.1977.tb00673.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yee Y. G., Rubin P., Blaschke T. F. Atenolol determination by high-performance liquid chromatography and fluorescence detection. J Chromatogr. 1979 Apr 1;171:357–362. doi: 10.1016/s0021-9673(01)95315-4. [DOI] [PubMed] [Google Scholar]